BridgeBio Pharma (NASDAQ:BBIO) Stock Acquired by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros, Jr. disclosed purchasing $1,001–$15,000 of BridgeBio Pharma shares through a trust account.
• BridgeBio reported quarterly revenue of $353.17 million, up 192.6% year over year, and a loss of $0.42 per share—better than analysts’ estimates on both revenue and EPS.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $104.26; 19 analysts rate the stock Buy, two Hold, and one Sell.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on November 2nd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of argenex NASDAQ: ARGX on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Illumina NASDAQ: ILMN on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Revvity NYSE: RVTY on 10/27/2026.
• Sold $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 10/27/2026.
• Purchased $1,001 - $15,000 in shares of MACOM Technology Solutions NASDAQ: MTSI on 10/27/2026.
• Sold $1,001 - $15,000 in shares of Micron Solutions OTCMKTS: MICR on 10/21/2026.
• Sold $1,001 - $15,000 in shares of Ciena NYSE: CIEN on 10/21/2026.
• Purchased $1,001 - $15,000 in shares of ServiceNow NYSE: NOW on 10/21/2026.
• Purchased $1,001 - $15,000 in shares of Moderna NASDAQ: MRNA on 10/20/2026.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $79.54 on Thursday. The company has a market cap of $15.49 billion, a P/E ratio of -26.16 and a beta of 0.97. The firm has a 50-day moving average of $69.89 and a 200-day moving average of $72.79. BridgeBio Pharma, Inc. has a one year low of $62.50 and a one year high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.12. The business had revenue of $353.17 million for the quarter, compared to the consensus estimate of $293.47 million. The business's revenue was up 192.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.95) earnings per share. As a group, research analysts expect that BridgeBio Pharma, Inc. will post -2.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Landscape Capital Management L.L.C. bought a new position in BridgeBio Pharma during the third quarter valued at about $605,000. Teachers Retirement System of The State of Kentucky raised its stake in shares of BridgeBio Pharma by 322.1% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 77,644 shares of the company's stock valued at $5,109,000 after acquiring an additional 59,248 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of BridgeBio Pharma by 0.9% in the 3rd quarter. HighTower Advisors LLC now owns 46,263 shares of the company's stock valued at $3,044,000 after acquiring an additional 432 shares in the last quarter. Ground Swell Capital LLC acquired a new stake in BridgeBio Pharma in the 3rd quarter worth approximately $372,000. Finally, Aberdeen Group plc acquired a new stake in BridgeBio Pharma in the 3rd quarter worth approximately $19,862,000. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Buying and Selling

In other BridgeBio Pharma news, CEO Neil Kumar sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $69.08, for a total transaction of $690,800.00. Following the transaction, the chief executive officer owned 495,686 shares in the company, valued at $34,241,988.88. This trade represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $72.85, for a total transaction of $145,700.00. Following the completion of the transaction, the chief accounting officer directly owned 120,687 shares in the company, valued at approximately $8,792,047.95. This represents a 1.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,980 shares of company stock valued at $4,563,699 in the last ninety days. Company insiders own 14.23% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on BBIO. Canaccord Genuity Group increased their target price on shares of BridgeBio Pharma from $106.00 to $108.00 and gave the stock a "buy" rating in a research report on Monday, November 2nd. UBS Group restated a "buy" rating on shares of BridgeBio Pharma in a report on Friday, October 30th. Truist Financial upped their price target on shares of BridgeBio Pharma from $102.00 to $107.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Jefferies Financial Group reiterated a "buy" rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Nineteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $104.26.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BridgeBio Pharma Company Profile

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.